Company

Clinical stage company commited to develop to market novel,
non-invasive, take home products for unmet aesthetic needs
  • EpiPharm AG is a clinical-stage biopharmaceutical company focused on development to market of innovative, non-invasive, take home topical products for the treatment of benign skin tumours and hyperpigmentation disorders.

  • EPI-SK17, EpiPharm’s lead product is the first therapy that treats the cause of seborrheic keratosis, the underlying tumour formation and growth.
    EpiPharm is further developing treatments for other indications through line extensions of its proprietary discoveries.

 

Management Team

Highly experienced senior pharma executives

Dr. Rosemarie Sift Carter

CEO

Extensive experience in research and drug development, (Ciba, Novartis, Janssen, Roche) and regulatory affairs (Swissmedic). Degrees in pharmacy, pharmacoepidemiology, PhD in natural sciences.

Dr. Robert Carter

Head Development and Regulatory

Very broad background in pharmaceutical operations, development, quality, regulatory affairs, production and sales (Abbott, BASF Pharma, Ciba-Geigy, Arpida, Acino). Degree in chemical & PhD in biochemical engineering.

Jean Lüchinger

Executive Board Member.

Career in pharma marketing and fine chemicals at Sandoz and Roche. Acquired toll manufacturer Cimex and led its successful IPO and later acquisition. Master of Science in chemistry and in economics.

Andres Huber

CFO

Over 30 years of banking and project financing experience (UBS, Crédit Commercial de France and Swiss Bank Corporation, CFO Cimex Pharma AG). Swiss degree in banking and finance.

Partnering
 
EpiPharm’s pipeline offers numerous opportunities for co-development or licensing
 

EpiPharm’s pipeline offers numerous opportunities for co-development or licensing of its projects targeting a range of pigmented lesions.

In case of interest please contact us at info-at-epipharm.ch or one of the team members:

 
 
Advisors and Network
Renowned experts

EpiPharm is proud to have engaged experts
in different fields of drug development.

    • Prof. A. Dayan: University of London, UK, Preclinical Safety
    • Prof. R. Haynes: HKUST, HK, Medicinal Chemistry
    • Prof. Dr. med. T. Jung: CH, Clinical Development
    • Dr. A. Watkinson: Storith Consulting, UK, Formulation Development
    • Dr. med. A Härtel: CH, Medical Consultant
    • Medpharm: UK, Formulation Development
    • Glaropharm: CH, Manufacturing
    • Scarletred:  AT, Imaging